New patent expiration for Pf Prism drug XELJANZ
Annual Drug Patent Expirations for XELJANZ Xeljanz is a drug marketed by Pfizer and Pf Prism Cv and is included […]
Patent Expiration
New patent expiration for Glaxosmithkline drug TRELEGY ELLIPTA
Annual Drug Patent Expirations for TRELEGY+ELLIPTA Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA.
New patent expiration for Glaxosmithkline drug TRELEGY ELLIPTA Read Post »
New patent expiration for Glaxosmithkline drug ANORO ELLIPTA
Annual Drug Patent Expirations for ANORO+ELLIPTA Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA.
New patent expiration for Glaxosmithkline drug ANORO ELLIPTA Read Post »
New patent expiration for Glaxo Grp drug BREO ELLIPTA
Annual Drug Patent Expirations for BREO+ELLIPTA Breo Ellipta is a drug marketed by Glaxo Grp Ltd and is included in
New patent expiration for Glaxo Grp drug BREO ELLIPTA Read Post »
Drug Patent Expirations for the Week of March 19, 2023
INBRIJA (levodopa) Acorda Patent: 9,155,699 Expiration: Mar 19, 2023 See More … For more information on how DrugPatentWatch can help
Drug Patent Expirations for the Week of March 19, 2023 Read Post »
New patent expiration for Kastle Theraps drug KYNAMRO
Annual Drug Patent Expirations for KYNAMRO Kynamro is a drug marketed by Kastle Theraps Llc and is included in one
New patent expiration for Kastle Theraps drug KYNAMRO Read Post »
New patent expiration for Akcea Theraps drug TEGSEDI
Annual Drug Patent Expirations for TEGSEDI Tegsedi is a drug marketed by Akcea Theraps and is included in one NDA.
New patent expiration for Akcea Theraps drug TEGSEDI Read Post »
New patent expiration for Amgen Inc drug OTEZLA
Annual Drug Patent Expirations for OTEZLA Otezla is a drug marketed by Amgen Inc and is included in one NDA.
New patent expiration for Acorda drug INBRIJA
Annual Drug Patent Expirations for INBRIJA Inbrija is a drug marketed by Acorda and is included in one NDA. It
